David Owens

List of Publications by Year
in descending order

77 papers	5,026 citations	136885 32 h-index	88593 70 g-index
77 all docs	77 docs citations	77 times ranked	4948 citing authors

#	Article	IF	Citations
1	The Loss of Postprandial Glycemic Control Precedes Stepwise Deterioration of Fasting With Worsening Diabetes. Diabetes Care, 2007, 30, 263-269.	4.3	419
2	Glycaemic variability in diabetes: clinical and therapeutic implications. Lancet Diabetes and Endocrinology,the, 2019, 7, 221-230.	5.5	363
3	Insulins today and beyond. Lancet, The, 2001, 358, 739-746.	6.3	353
4	Alternative routes of insulin delivery. Diabetic Medicine, 2003, 20, 886-898.	1.2	307
5	Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet, The, 2008, 371, 1073-1084.	6.3	295
6	Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes. Diabetes Care, 2017, 40, 832-838.	4.3	262
7	IDF Diabetes Atlas: A review of studies utilising retinal photography on the global prevalence of diabetes related retinopathy between 2015 and 2018. Diabetes Research and Clinical Practice, 2019, 157, 107840.	1.1	202
8	New horizons â€" alternative routes for insulin therapy. Nature Reviews Drug Discovery, 2002, 1, 529-540.	21.5	182
9	Prevalence of diabetic retinopathy within a national diabetic retinopathy screening service. British Journal of Ophthalmology, 2015, 99, 64-68.	2.1	158
10	The Contribution of Glucose Variability to Asymptomatic Hypoglycemia in Persons with Type 2 Diabetes. Diabetes Technology and Therapeutics, 2011, 13, 813-818.	2.4	147
11	Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses. Diabetologia, 2021, 64, 275-287.	2.9	140
12	Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia, 2010, 53, 562-571.	2.9	126
13	Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attending the Diabetic Retinopathy Screening Service for Wales: retrospective analysis. BMJ: British Medical Journal, 2012, 344, e874-e874.	2.4	114
14	Review of methods for detecting glycemic disorders. Diabetes Research and Clinical Practice, 2020, 165, 108233.	1.1	108
15	Differential effects of glucagon-like peptide-1 receptor agonists on heart rate. Cardiovascular Diabetology, 2017, 16, 6.	2.7	107
16	Insulin Preparations with Prolonged Effect. Diabetes Technology and Therapeutics, 2011, 13, S-5-S-14.	2.4	103
17	When basal insulin therapy in type 2 diabetes mellitus is not enoughâ€"what next?. Diabetes/Metabolism Research and Reviews, 2007, 23, 257-264.	1.7	102
18	Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Lancet, The, 2012, 379, 2262-2269.	6.3	100

#	Article	IF	Citations
19	Magnitude of the Dawn Phenomenon and Its Impact on the Overall Glucose Exposure in Type 2 Diabetes. Diabetes Care, 2013, 36, 4057-4062.	4.3	87
20	Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month â€˜proof-of-concept' study. Diabetes, Obesity and Metabolism, 2011, 13, 1020-1027.	2.2	83
21	Basal insulin analogues in the management of diabetes mellitus: what progress have we made?. Diabetes/Metabolism Research and Reviews, 2014, 30, 104-119.	1.7	83
22	Beyond the Era of NPH Insulinâ€”Long-Acting Insulin Analogs: Chemistry, Comparative Pharmacology, and Clinical Application. Diabetes Technology and Therapeutics, 2008, 10, 333-349.	2.4	78
23	Clinical Evidence for the Earlier Initiation of Insulin Therapy in Type 2 Diabetes. Diabetes Technology and Therapeutics, 2013, 15, 776-785.	2.4	72
24	Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus. Diabetes and Metabolism, 2013, 39, 485-496.	1.4	66
25	Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes. Diabetes Care, 2000, 23, 518-523.	4.3	62
26	The Emergence of Biosimilar Insulin Preparationsâ€”A Cause for Concern?. Diabetes Technology and Therapeutics, 2012, 14, 989-996.	2.4	60
27	The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications. Diabetes, Obesity and Metabolism, 2020, 22, 743-754.	2.2	50
28	Does bariatric surgery adversely impact on diabetic retinopathy in persons with morbid obesity and type 2 diabetes? A pilot study. Journal of Diabetes and Its Complications, 2014, 28, 191-195.	1.2	47
29	Respective Contributions of Glycemic Variability and Mean Daily Glucose as Predictors of Hypoglycemia in Type 1 Diabetes: Are They Equivalent?. Diabetes Care, 2020, 43, 821-827.	4.3	41
30	Stepwise intensification of insulin therapy in TypeÂ2 diabetes managementâ€”exploring the concept of the basalâ€plus approach in clinical practice. Diabetic Medicine, 2013, 30, 276-288.	1.2	40
31	A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period. Diabetes Research and Clinical Practice, 2008, 79, 269-275.	1.1	37
32	Glucose variability and diabetes complications: Risk factor or biomarker? Can we disentangle the â€œGordian Knotâ€?. Diabetes and Metabolism, 2021, 47, 101225.	1.4	34
33	Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy. Diabetes Research and Clinical Practice, 2017, 124, 57-65.	1.1	33
34	Future challenges and therapeutic opportunities in type 2 diabetes: <scp>C</scp>hanging the paradigm of current therapy. Diabetes, Obesity and Metabolism, 2017, 19, 1339-1352.	2.2	33
35	The burden of type 2 diabetes in Europe: Current and future aspects of insulin treatment from patient and healthcare spending perspectives. Diabetes Research and Clinical Practice, 2020, 161, 108053.	1.1	33
36	Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: A pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials. Diabetes Research and Clinical Practice, 2014, 106, 264-274.	1.1	32

#	Article	IF	Citations
37	Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 977-987.	1.5	32
38	Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes. Diabetes, Obesity and Metabolism, 2011, 13, 251-257.	2.2	30
39	Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials. Diabetes Therapy, 2016, 7, 187-201.	1.2	29
40	Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190â€‰Âµg intravitreal implant in people with diabetic macular edema. Current Medical Research and Opinion, 2017, 33, 5-17.	0.9	27
41	Retrospective analysis of newly recorded certifications of visual impairment due to diabetic retinopathy in Wales during 2007â€“2015. BMJ Open, 2017, 7, e015024.	0.8	27
42	A review of glucagonâ€like peptideâ€1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2017, 19, 1645-1654.	2.2	24
43	Effect of structured selfâ€monitoring of blood glucose, with and without additional TeleCare support, on overall glycaemic control in nonâ€insulin treated Type 2 diabetes: the SMBG Study, a 12â€month randomized controlled trial. Diabetic Medicine, 2019, 36, 578-590.	1.2	22
44	Insulin glargine (Lantus). International Journal of Clinical Practice, 2002, 56, 460-6.	0.8	21
45	Thiazolidinediones. Clinical Drug Investigation, 2002, 22, 485-505.	1.1	20
46	Diabetic Retinopathy in Newly Diagnosed Subjects With Type 2 Diabetes Mellitus: Contribution of Î²-Cell Function. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 572-580.	1.8	15
47	Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0%. Diabetes, Obesity and Metabolism, 2019, 21, 321-329.	2.2	15
48	Evaluation of the clinical effectiveness of fluocinolone acetonide 190â€‰Âµg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes. Current Medical Research and Opinion, 2017, 33, 19-31.	0.9	14
49	Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190â€‰Âµg intravitreal implant for diabetic macular edema. Current Medical Research and Opinion, 2017, 33, 33-43.	0.9	14
50	Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 22 and Metabolism, 2019, 45, 330-340.	1.4	14
51	Fasting Câ€peptide, a biomarker for hypoglycaemia risk in insulinâ€naÃ¯ve people with type 2 diabetes initiating basal insulin glargine 100â€‰U/mL. Diabetes, Obesity and Metabolism, 2020, 22, 315-323.	2.2	13
52	Self-monitoring of Blood Glucose in Non-Insulin Treated Type 2 Diabetes (The SMBG Study): study protocol for a randomised controlled trial. BMC Endocrine Disorders, 2017, 17, 4.	0.9	12
53	Cost-effectiveness of biennial screening for diabetes related retinopathy in people with type 1 and type 2 diabetes compared to annual screening. European Journal of Health Economics, 2020, 21, 993-1002.	1.4	11
54	Glargine and Cancer: Can We Now Suggest Closure?. Diabetes Care, 2012, 35, 2426-2428.	4.3	10

#	Article	IF	Citations
55	The impact of structured self-monitoring of blood glucose on glycaemic variability in non-insulin treated type 2 diabetes: The SMBG study, a 12-month randomised controlled trial. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 101-106.	1.8	10
56	Glycaemic variabilities: Key questions in pursuit of clarity. Diabetes and Metabolism, 2021, 47, 101283.	1.4	9
57	Repaglinide: prandial glucose regulation in clinical practice. Diabetes, Obesity and Metabolism, 2000, 2, S43-S48.	2.2	8
58	Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treatâ€toâ€target trials with insulin glargine 100â€‰U/<scp>mL</scp> added to oral antidiabetes agents in type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 1546-1554.	2.2	8
59	Recombinant Human Insulin in Global Diabetes Management â€“ Focus on Clinical Efficacy. European Endocrinology, 2017, 13, 21.	0.8	8
60	Characteristics of repeat nonâ€attenders at Diabetes Eye Screening Wales, a national communityâ€based diabetesâ€related retinopathy screening service, during 2003â€2018. Diabetic Medicine, 2021, 38, e14536.	1.2	8
61	Insulin Centennial: Milestones influencing the development of insulin preparations since 1922. Diabetes, Obesity and Metabolism, 2022, 24, 27-42.	2.2	8
62	Risk factors for having diabetic retinopathy at first screening in persons with type 1 diabetes diagnosed under 18 years of age. Eye, 2021, 35, 2840-2847.	1.1	7
63	One-hundred year evolution of prandial insulin preparations: From animal pancreas extracts to rapid-acting analogs. Metabolism: Clinical and Experimental, 2022, 126, 154935.	1.5	7
64	Insulin sensitivity in Type 2 diabetes: univariate and multivariate techniques to derive estimates of insulin sensitivity from the insulin modified intravenous glucose tolerance test (FSIGT). Computer Methods and Programs in Biomedicine, 2002, 68, 161-176.	2.6	6
65	Efficacy and safety of linagliptin in type 2 diabetes patients with self-reported hepatic disorders: A retrospective pooled analysis of 17 randomized, double-blind, placebo-controlled clinical trials. Journal of Diabetes and Its Complications, 2016, 30, 1622-1630.	1.2	6
66	Early-phase prandial insulin secretion: its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide. Diabetes, Nutrition & Metabolism, 2002, 15, 19-27.	0.4	6
67	Evaluation of a New Neural Network Classifier for Diabetic Retinopathy. Journal of Diabetes Science and Technology, 2022, 16, 1401-1409.	1.3	5
68	Optimizing treatment strategies with insulin glargine in Type 2 diabetes. Expert Review of Endocrinology and Metabolism, 2012, 7, 377-393.	1.2	4
69	When should screening for diabetic retinopathy begin for children with type 1 diabetes?. Expert Review of Endocrinology and Metabolism, 2016, 11, 97-102.	1.2	4
70	Below Which Threshold of Glycemic Variability Is There a Minimal Risk of Hypoglycemia in People with Type 2 Diabetes?. Diabetes Technology and Therapeutics, 2022, 24, 453-454.	2.4	4
71	Hypoglycaemia risk in the first 8 weeks of titration with insulin glargine 100 U/mL in previously insulinâ€naive individuals with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2018, 20, 2894-2898.	2.2	3
72	A retrospective epidemiological study of Type 1 Diabetes Mellitus in Wales, UK between 2008 and 2018. International Journal of Population Data Science, 2021, 6, 1387.	0.1	3

#	Article	IF	Citations
73	Insulin glargine: commentary on the duration of action and lower risk of nocturnal hypoglycaemia in patients with diabetes. Expert Opinion on Pharmacotherapy, 2004, 5, 1-3.	0.9	1
74	New Meta-Analysis of Patient-Level Data on Efficacy And Hypoglycaemia with Insulin Glargine or Nph Insulin in Type 2 Diabetes Mellitus (T2DM) According to Concomitant Oral Therapy. Value in Health, 2014, 17, A335.	0.1	1
75	Si l'Ã¨re des insulines semi-synthÃ©tiques et biosynthÃ©tiques nous Ã©tait contÃ©e. Medecine Des Maladies Metaboliques, 2021, 15, 3S32-3S52.	0.1	1
76	Response Letter to D. Singhâ€Franco et al.. Diabetes, Obesity and Metabolism, 2012, 14, 1054-1055.	2.2	0
77	The quest for physiologic insulin replacement. Postgraduate Medicine, 2004, 116, 4-12.	0.9	0